Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.14 USD | -2.84% | +15.40% | +40.59% |
24/05 | JPMorgan Adjusts Price Target on Cellebrite DI to $14 From $12, Maintains Overweight Rating | MT |
24/05 | Deutsche Bank Adjusts Price Target on Cellebrite to $15 From $13, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.59% | 2.57B | |
+13.98% | 90.53B | |
+12.11% | 85.46B | |
+35.24% | 52.93B | |
-19.29% | 52.56B | |
+33.05% | 47.67B | |
+84.20% | 42.43B | |
-34.32% | 42.38B | |
-1.31% | 27.82B | |
-20.56% | 23.06B |
- Stock Market
- Equities
- CLBT Stock
- News Cellebrite DI Ltd.
- Cellebrite DI Swings to Q2 Adjusted Earnings, Revenue Increases; Raises 2023 Sales Outlook